Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: J Immunother. 2015 Jun;38(5):197–210. doi: 10.1097/CJI.0000000000000082

Fig. 5. Improved intratumoral infiltration of CXCR4-engineered YTS-NK cells into U87-MGEGFRvIII/SDF-1α-xenografts.

Fig. 5

a: YTS cells were transduced with DsRed and established YTSDsRed cells were further genetically modified to express CXCR4. Depicted are the flow cytometry histograms showing DsRed expression (filled histogram). CXCR4 expression was detected using a monoclonal anti-CXCR4 antibody coupled to APC (filled histogram). Wild type cells and isotype stained cells, respectively, are included as control (dotted line). b: CXCL12/SDF-1α-secreting U87-MGEGFRvIII/SDF-1α and U87-MGEGFRvIII/EGFP control cells were subcutaneously injected into the right flank of NMRI-Foxn1nu/Foxn1nu mice. After tumor development, mice were treated with intravenous tail vein injections with either YTSDsRed/CXCR4 or YTSDsRed cells and the number of infiltrated DsRed+ cells in tumors was analyzed per field of view (40× objective). YTSDsRed/CXCR4 cells showed an improved intra-tumoral accumulation in U87-MGEGFRvIII/SDF-1α tumors when compared to all controls. **p < 0.01; n.s., not significant. The experiment was repeated twice with similar results.